Compare Transocean Ltd (RIG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Transocean Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Transocean Ltd trades at $5.75 (market cap $6.43B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 20.8× Transocean Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Transocean Ltd nearer its low. Which is the better fit depends on your goals.
| RIG | VRTX | |
|---|---|---|
Market Cap | $6.43B | $134.06B |
Sector | Technology | Health |
52-Week High | $7.58 | $557.96 |
52-Week Low | $3.08 | $376.62 |
Enterprise Value | $11.04B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Transocean (RIG) trades at $5.76, down 1.54% today, with a bearish technical signal despite recent earnings beat. The company shows improving operational cash flow ($995M in 2026) and secured a $300M contract with ONGC, but faces challenges with negative net income margins (-40.24%) and high debt levels. Analyst sentiment is mixed with 39% buy ratings amid ongoing profitability concerns.
RIG presents a high-risk opportunity with improving contract backlog and cash flow generation potential offset by substantial debt burden and inconsistent earnings performance. Investors should weigh the company's exposure to volatile oil prices against its position in the tightening deepwater drilling market.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
